Received by email:

File: CVR Medical.News Release (Sep. 26, 2018) (W0366052xB74B6).pdf

                       NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
                              OR FOR DISSEMINATION IN THE UNITED STATES



              CVR Medical Announces Closing of
                Second Tranche of Financing
VANCOUVER, BC / September 26, 2018 / CVR Medical Corp. CVR Medical Corp. (TSX.V:CVM)
(FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical") is pleased to announce that it has closed the second
tranche (the "Second Tranche") of its previously announced non-brokered private placement financing
(the "Financing").

An aggregate of 1,935,427 units ("Units") at a price of $0.30 per Unit were issued in the Second Tranche
for gross proceeds of $580,628.10. Dr. Paul Blunden, a Director of CVR Medical since CVR Medical's
inception and also involved with the development of the CSS Device from the beginning, participated in
this closing with an investment of $299,828.10. Due to timing and logistical issues, CVR Medical was not
able to accommodate all interested investors into the Second Tranche closing. As a result, CVR Medical
will take the necessary steps to proceed with a third tranche immediately to accommodate such investors.

Proceeds from the Financing will be used for ongoing working capital requirements relating to the
development and commercialization of the proprietary subsonic, infrasonic and low frequency sound wave
analysis technology and diagnostic device designed to detect and measure carotid arterial disease, known
as the CSS Device.

Each Unit consists of one common share of CVR Medical (each, a "Share") and one transferable common
share purchase warrant (each, a "Warrant"). Each Warrant is exercisable at a price of $0.36 until
September 21, 2023 (the "Expiry Time"), provided that if on any ten (10) consecutive trading days at any
time after January 22, 2019, the daily closing price of the Shares on the TSX Venture Exchange is at or
greater than $0.50, CVR Medical may provide notice to the holder of the early expiry (the "Notice") and
thereafter, the Warrants will expire on the date that is thirty (30) calendar days after the date of the Notice.

In the Second Tranche closing, CVR Medical did not pay any finder's fees.

The Shares and the Warrants are subject to a hold period expiring January 22, 2019. The Financing remains
subject to final acceptance of the TSX Venture Exchange.

The securities referred to herein will not be or have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the United States absent
registration or an applicable exemption from registration requirements.

About CVR Medical

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the
commercialization of its disruptive, proprietary CSS Device. The CSS device is a diagnostic tool that
encompasses subsonic, infrasonic, and low frequency sound wave analysis technology. The CSS Device
is a patented device designed to detect and measure carotid arterial stenosis. CVR is currently in pivotal
clinical trials in preparation for its planned submission to the FDA. CVR is led by an experienced and
proven team of professionals with extensive healthcare, medical device, international expansion, regulatory
and sales experience. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
Additional information regarding the Company can be found in our recent filings with the SEDAR as well
as the information maintained on our website at www.cvrmed.com
                        NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES
                              OR FOR DISSEMINATION IN THE UNITED STATES




ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Director

For further information contact:
Peter Bakema, CEO, President and Director
Email: info@cvrmed.com

or

Marc S. Lubow.
Vice President Capital Markets, Director of Investor Relations
904-923-4037
marclubow@cvrmed.com


This press release contains forward-looking information that involves various risks and uncertainties
regarding future events related to the Financing including the expected use of net proceeds from the
Financing. Such statements are subject to risks and uncertainties that may cause actual results,
performance or developments to differ materially from those contained in the statements and are not
guarantees of future performance of the Company. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company
will obtain from them. These forward-looking statements reflect management's current views and are based
on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and
uncertainties could cause our actual results to differ materially from those expressed or implied by the
forward-looking statements, including: (1) a downturn in general economic conditions in North America
and internationally, (2) the inherent uncertainties and speculative nature associated with
commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any
number of events or causes which may delay or cease commercialization and development of the Joint
Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability
to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the
Company's control. These forward-looking statements are made as of the date of this news release and,
except as required by law, the Company assumes no obligation to update these forward-looking statements,
or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE
CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS
REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE
TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.